Compared with an infusion into the vein, injecting Actemra (tocilizumab) under the skin offers people with systemic and polyarticular juvenile idiopathic ... Read more
Versus Arthritis has funded three more years of research into therapies for juvenile arthritis and related conditions at the U.K. Experimental ... Read more
The European Commission (EC) has approved Yuflyma (CT-P17), an adalimumab biosimilar, to treat multiple chronic inflammatory diseases, including juvenile idiopathic arthritis. ... Read more
A specific genetic signature can help in identifying children with systemic onset juvenile arthritis (sJIA) who are most likely to respond ... Read more
Uveitis, a form of eye inflammation, worsens vision and vision-related quality of life among children with juvenile idiopathic arthritis (JIA), according ... Read more
Use of a treat-to-target approach, combined with a tool to support clinical decisions, significantly lowered disease activity in children with polyarticular ... Read more
Significant changes were found in the immune cell levels of children with juvenile idiopathic arthritis (JIA) following treatment with methotrexate and ... Read more
An analysis using machine learning identified distinct patient groups and disease activity trajectories among young patients in the U.K. with juvenile idiopathic arthritis ... Read more
